Ovarian Masses in Children: Surgical Experience and Outcomes Authors: Rohit Kapoor, Ankur Mandelia, Basant Kumar, Vijai Datta Upadhyaya, Anju Verma, Pujana Kanneganti, Tarun Kumar, Nishant Agarwal, Rahul Goel, Pooja Prajapati Published: 2024 ABSTRACT ABSTRACTAims:This study aims to review our experience of treating ovarian masses in children with an emphasis on clinical presentation, diagnosis, treatment, and outcome.Methods:We retrospectively reviewed the electronic medical records of all patients below 18 years of age who underwent surgical treatment for ovarian masses at our institute between 2009 and 2023. Study variables included demography, clinical presentation, physical findings, tumor markers, radiologic features, operative details, histopathology, follow-up status, and overall survival.Results:During the study period, 30 patients with a mean age of 10.07 years (range: 15 days–18 years) underwent surgical treatment for ovarian masses. Nonneoplastic ovarian masses were seen in 5 (16.7%) patients, whereas 25 (83.3%) patients had benign (10 [33.3%], borderline 3 [10%], or malignant 12 [40%]) ovarian neoplasms. The most common clinical presentation in the benign group was abdominal pain (n = 6), whereas painless abdominal mass (n = 6) was the predominant complaint in children with malignant tumors. A functional ovarian mass presenting with precocious puberty or virilization was seen in 5 (16.7%) patients. On imaging, nonneoplastic and benign lesions had a mean size of 4.33 (range: 3.1–6) cm and 12.63 (range: 2.8–28) cm, respectively, whereas borderline and malignant masses had a mean tumor size of 22.5 (range: 6.5–32) cm and 12.55 (range: 3.5–18.7) cm, respectively (P < 0.05). The cystic component was identified in all nonneoplastic and benign tumors, whereas the solid component was present in all borderline and malignant lesions (P < 0.05). Tumor markers such as serum alpha-fetoprotein and beta-human chorionic gonadotropin were raised in 8 (66.67%) of malignant tumors, whereas markers were normal in all benign lesions and borderline malignant lesions and 4 (33.33%) of malignant tumors. Lactate dehydrogenase (LDH) was also raised in all malignant masses (n = 12), whereas it was normal in all benign and borderline malignant masses (n = 18). In 6 (20%) patients with nonneoplastic and benign masses with maximum tumor size <6 cm, the laparoscopic approach was adopted, whereas open surgery was preferred in the rest of the patients. At a mean follow-up of 53.5 (range: 4–117) months, all patients are alive and disease free.Conclusions:Preoperative imaging characteristics (tumor size and solid component) and raised tumor markers may help us to differentiate between benign and malignant ovarian pathologies. The overall prognosis of pediatric ovarian tumors seems to be favorable. INTRODUCTION Pediatric ovarian masses are rare, having an annual incidence of 2.6 per 100,000 girls, accounting for approximately 1% of all tumors in children and adolescents.[1] The difference in incidence as per the geographic distribution is striking, with an incidence as high as 8 in 100,000 in western countries, and as low as <3 per 100,000 in Asian countries like India.[2] Ovarian tumors can present as an acute abdominal emergency due to torsion/rupture or may present insidiously with a large pelvic or abdominal mass with or without pain. Ovarian masses in children include a wide pathological spectrum, ranging from functional ovarian cysts to benign and even highly malignant lesions. Approximately 50% of ovarian masses in children are neoplastic in nature and 16%–55% of these are malignant, depending on reference population, age cutoffs, and inclusion of nonneoplastic cysts.[34] Historically, all ovarian masses discovered in infants, children, and adolescents were removed surgically. However, the preservation of ovarian function and future fertility potential are important concerns in the pediatric age group. Advances in imaging techniques combined with appropriate tumor markers can help to accurately differentiate benign from malignant ovarian lesions and help us achieve the goal of ovarian preservation whenever feasible.[5] Although there is a plethora of research publications on this topic, they tend to differ on management strategies such as the use of adjuvant therapy in borderline malignant and early-stage malignant masses.[6] With this study, we aim to review our experience of treating ovarian masses in children with an emphasis on clinical presentation, diagnosis, treatment, and outcomes and add to the existing literature. METHODS This study was performed in accordance with the ethical standards of the institutional and/or National Research Committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Ethical approval was waived in view of the retrospective nature of the study and as the patient’s identity and details were not revealed in any part of the manuscript or figures. The electronic medical records of all patients below 18 years of age who underwent surgical treatment for ovarian masses at our institute between 2009 and 2023 were retrospectively reviewed. Patients, who did not complete treatment or were lost on follow-up, were excluded from the study. Study variables included demography, clinical presentation, physical findings, tumor markers, radiologic features, operative details, histopathology, follow-up status, and overall survival (OS). All the patients were diagnosed using ultrasonography (USG), whereas advanced imaging such as contrast-enhanced computed tomography (CECT) of the chest, abdomen, and pelvis was done in all patients to assess detailed tumor characteristics, resectability, and metastasis. Tumor markers, such as alpha-fetoprotein (AFP), beta-human chorionic gonadotropin (Hcg), CA-125, and LDH, were done in all the patients. Ovarian preservation surgery was performed for nonneoplastic and benign lesions when feasible and oophorectomy was performed when malignancy was confirmed or suspected on preoperative evaluation (solid/echogenic lesion on USG, size >8 cm, and positive tumor markers) as per our institutional protocol for such cases. If a tumor was >8 cm in size but had negative tumor markers, an oophorectomy was performed if ovarian tissue was not seen separately from the mass intraoperatively and oophorectomy was deemed necessary to completely clear the disease. The staging used was Federation of Gynecology and Obstetrics staging for epithelial neoplasms and Children’s Oncology Group (COG) staging for germ cell neoplasms of the ovary.[78] All the patients with Stage IIIC and IV disease on presentation were given neoadjuvant chemotherapy before surgery followed by adjuvant chemotherapy as per the Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline.[9] Furthermore, all the patients were followed up postoperatively, and chemotherapy was given if the mass was reported as malignant on histopathology. The chemotherapy regimen used was platinum-based PEB (cisplatin, etoposide, and bleomycin) regimen as per the latest COG guidelines for ovarian germ cell tumors (GCTs).[8] All the patients with malignant pathology and raised tumor markers preoperatively were followed up by 3 monthly tumor marker levels and USG in first year, and 6 monthly tumor marker levels and USG in second year, and then were called for follow-up yearly as per our institutional protocol. RESULTS During the study period (2009–2022), 30 patients with a median age of 11 years (interquartile range: 15 days–18 years) underwent surgical treatment for ovarian masses at our institute. Based on postoperative histopathology, all patients were classified into two groups: Group 1 included nonneoplastic/benign ovarian masses (n = 15; 50%) and Group 2 included borderline malignant/malignant ovarian masses (n = 15; 50%) [Table 1]. Table 1Histopathological ClassificationHistopathological DiagnosisNo. of patients (% of total) n=30GroupNon-neoplastic5 (16.7)Haemorrhagic Cyst3 (10)Simple Cyst1 (3.3)Follicular Cyst1 (3.3)Neoplastic25 (83.3) Benign10 (33.3) Mature Teratoma6 (20) Cystadenoma3 (10) Well differentiated Sertoli/Leydig cell tumor1 (3.3) Borderline3 (10) Borderline Cystadenoma (mucinous or serous)2 (6.7) Juvenile granulose cell tumor1 (3.3) Malignant12 (40) Germ Cell Tumour Dysgerminoma2 (6.7) Mixed Germ cell tumor9 (30) Immature Teratoma1 (3.3) Histopathological Classification The most common clinical presentation in nonneoplastic/benign group was abdominal pain (n = 6), whereas painless abdominal mass (n = 6) was the predominant complaint in children with malignant/borderline malignant tumors [Table 2]. A functional ovarian mass presenting with precocious puberty or virilization was seen in 5 (18.5%) patients out of which 4 were in nonneoplastic/benign group, whereas only 1 was in the borderline malignant/malignant group. On imaging, nonneoplastic and benign lesions had a mean size of 4.33 (range: 3.1–6) cm and 12.63 (range: 2.8–28) cm, respectively; whereas borderline and malignant masses had a mean tumor size of 22.5 (range: 6.5–32) cm and 12.55 (range: 3.5–18.7) cm, respectively. Pure cystic component was identified in most nonneoplastic and benign tumors (n = 10; 67%), whereas pure solid component was present in 8 (56%) borderline and malignant lesions. Furthermore, in our series, 5 (33%) patients with nonneoplastic and benign histopathology (Group 1) and 7 (44%) with malignant and borderline malignant histopathology (Group 2) had both solid and cystic components on USG. Tumor markers such as serum AFP and beta-HCG were raised in 8 (66.67%) of malignant tumors, whereas markers were normal in all benign lesions and borderline malignant lesions and 4 (33.33%) of malignant tumors [Table 2]. LDH was also raised in all malignant masses (n = 12), whereas it was normal in all benign and borderline malignant masses (n = 18). Table 2Demography, clinical presentation, imaging features, and tumor markersStudy variablesNonneoplastic and benign (n=15)Borderline malignant and malignant (n=15)Mean age (years)9.47±6.1010.67±4.30Presenting symptomsPain abdomen (n=6)Mass in abdomen (n=6)Mass in the abdomen (n=3)Pain and mass (n=4)Both pain and mass (n=1) Precautious puberty/functional (n=4)Urinary complaints with or without fever (n=2) Incidental (n=2)Pain abdomen and fever (n=1)Functional (n=1)Preoperative imagingMean size (cm)9.86±8.7714.54±8.5Range (cm)2.8–283.5–32Nature on USHypoechoic/cystic (n=9)Cystic with solid (n=7)Cystic with solid (n=5)Solid (n=8)Hyperechoic (n=1)Tumor markersRaised AFP (n=0)Raised AFP (n=10)Raised beta HCG (n=0)Raised beta HCG (n=2)Others (n=0)Others (n=5)Normal markers (n=4)US: Ultrasound, AFP: Alpha-fetoprotein, HCG: Human chorionic gonadotropin Demography, clinical presentation, imaging features, and tumor markers US: Ultrasound, AFP: Alpha-fetoprotein, HCG: Human chorionic gonadotropin In 6 (20%) patients with nonneoplastic and benign masses, the laparoscopic approach was adopted, whereas open surgery was preferred in the rest of the patients [Table 3]. In all patients undergoing laparoscopy, the maximum tumor size was 6 cm. The criteria for choosing laparoscopy in these cases were the nature of the ovarian mass, surgeon’s experience, and preference, and no size criteria were followed. Among the patients managed laparoscopically, oophorectomy was done in 5 (16.67%) patients, whereas ovary preserving cystectomy was done in 1 (4.3%) patient. Among all the patients managed by open surgery, oophorectomy was done in 23 (76.66%), whereas ovary preserving surgery was done in 1 patient in Group 1. Out of 15 patients with borderline malignant/malignant histopathology, 6 patients with suspected advanced malignancy (based on raised tumor markers and/or imaging findings) were given neoadjuvant chemotherapy and also complete course of adjuvant chemotherapy, whereas 4 patients were given adjuvant chemotherapy after malignancy was detected on histopathology. At a mean follow-up of 53.5 (range: 4–117) months, all patients are alive and disease free [Table 3]. Table 3Treatment and follow-upTreatmentNonneoplastic and benign (n=15)Borderline malignant and malignant (n=15)Surgery Open surgery (n=24)915 Oophorectomy (n=23)815 Ovary preserving (n=1)10 Laparoscopic surgery (n=6)60 Oophorectomy (n=5)50 Ovary preserving (n=1)10Chemotherapy010 Neoadjuvant + adjuvant (n)-6 Adjuvant (n)-4No adjuvant therapy155Median follow-up (months)5450 Treatment and follow-up DISCUSSION The vast majority of ovarian masses in children are nonneoplastic or benign and only about one-third of all pediatric ovarian masses are reported to be malignant.[34] Nonneoplastic cystic ovarian masses are commonly seen in children due to physiological ovarian stimulation in different age groups such as due to maternal and placental hormones in infancy, release of gonadotropins by developing pituitary in the prepubertal period, and dysfunctional ovulation in adolescence. The real challenge in the management of children with ovarian masses lies in the early detection and treatment of the small percentage of neoplastic, especially malignant lesions. Although clinical features, imaging, and tumor markers may help us differentiate benign from malignant lesions peroperatively, often the final diagnosis cannot be conclusively made unless histopathology of excised tumor is available. In our series, the mean age at presentation for the entire cohort was 10.06 ± 5.22 years (range: 15 days–18 years). This was not significantly different in both benign and malignant groups [Table 2] and is similar to the age range reported in the literature previously.[6] Presenting symptoms and signs of ovarian masses are generally nonspecific and include pain abdomen, abdominal lump, functional symptoms, etc., and they generally do not help to differentiate benign from malignant masses.[10] However, in our series, abdominal pain was the most common presenting symptom for nonneoplastic and benign masses, whereas a painless abdominal lump was the most common presentation for malignant lesions. Ovarian masses may also present with functional symptoms such as hirsutism or precautious puberty due to the secretion of hormones such as testosterone and estrogen, respectively. In our experience, 5 patients had functional ovarian masses who presented with precocious puberty and most of these lesions were nonneoplastic or benign (n = 4). On imaging studies such as USG and CECT, malignant tumors as predominantly solid, and benign tumors are usually cystic. In our series, predominantly cystic lesions on imaging were mostly benign, whereas predominantly solid lesions were ultimately diagnosed as malignant. However, in lesions with mixed solid and cystic consistency, differentiation into benign and malignant tumors based solely on radiological findings is often difficult. In our series, almost half (58%) of the tumors with mixed consistency on imaging were finally diagnosed as malignant or borderline malignant. The preoperative differentiation between benign and malignant is aided by combining imaging with tumor markers such as AFP, beta HCG, and CA-125 which were significantly elevated in the malignant group as compared to the benign group in our series. This is consistent with other reports in the literature.[11121314] Earlier, oophorectomy was the standard of care for all ovarian masses, but in recent times, surgical treatment has focused more on the principle of ovarian preservation while appropriately performing tumor resection.[15] The use of ovarian preservation is advocated primarily for benign lesions as ovarian preservation for malignancies carries a significantly higher risk of recurrence and is often not technically feasible. We performed ovary-sparing surgery when there was no irreversible ischemic damage to the ovary and the possibility of malignancy was minuscule based on preoperative investigations. Ipsilateral ovarian preservation was performed in two patients in our series, one with unilateral hemorrhagic ovarian cysts and the other with mature teratoma. The rest of the ovaries with benign cysts had undergone torsion and were beyond salvage at the time of surgery. Oophorectomy or tumorectomy can be performed using an open or laparoscopic approach; however, the use of laparoscopy is traditionally indicated for nonmalignant or benign tumors due to the potential risk of tumor rupture, spill, or port site recurrence during laparoscopic resection for malignant lesions. Laparoscopy confers all the advantages of minimal access surgery such as better visualization and magnification, shorter hospital stay, early feeding, and lesser requirement of analgesia. However, the decision to use this approach in children with ovarian masses should be individualized to each patient, depending on the experience and skill of the operating surgeon. In our series, the laparoscopic approach was used for 6/15 (40%) of nonmalignant/benign ovarian masses, especially in the later part of the study duration when we had gained experience in minimal access surgery. As per a recent meta-analysis,[16] mixed malignant GCTs are the most common (30%) malignant ovarian masses in children, followed by pure yolk sac tumors and dysgerminomas (20%), whereas sex cord-stromal tumors such as juvenile granulosa cell tumors were less common (14%). In our experience too, malignant mixed GCT was the most common pathology (30%), followed by dysgerminoma, whereas only 1 (3.3%) patient was diagnosed with juvenile granulosa cell tumor. Chemotherapy was given to 10/15 (66.7%) of Group 2 patients either as adjuvant chemotherapy (n = 4; Stage 2 and 3 tumors) or as neoadjuvant chemotherapy followed by adjuvant chemotherapy postsurgery (n = 6; Stage 4 tumors). The chemotherapy regimen used was platinum-based PEB (displaying, etoposide, and bleomycin) regimen as per the latest COG guidelines.[8] However, five patients of malignant/borderline malignant histopathology (Group 2) did not receive postoperative chemotherapy. Out of these 5, 2 patients were diagnosed as mucinous cystadenoma, one patient as juvenile granulosa cell tumor, one as Stage 1 and Grade 1 immature teratoma, and one as Stage 1 mixed GCT. All patients had normal preoperative tumor markers. The first four patients were not given any postoperative chemotherapy as surgical resection alone with free margins is considered curative in them with a very low risk of relapse.[6] All these patients are disease free on follow-up. The patient with Stage 1 mixed GCT histopathology was planned for adjuvant chemotherapy but was lost to follow-up for 2 years postoperatively. On her visit to follow-up clinic after 2 years, she was investigated for recurrence with imaging and tumor markers which were found to be normal. Currently, she is on regular 6-month follow-up and is disease free. As per the literature, OS for ovarian GCT ranges from 68% to 100%.[16] Earlier, when non platinum based chemotherapy was used, OS was lower. But now with advent of platinum-based chemotherapy, OS has improved considerably and approaches 100% in few series. No differences in survival are reported for histological subgroups in literature, including the study by Schneider et al.[17] on sex cord stromatolite tumors. In our series, at a median follow-up of 53.5 months (range: 4 months–114 months), OS was 100%, which can be attributed to protocol-based management using platinum-based chemotherapy at our institute. Our study has some limitations that warrant mention. First, as this is a single-center study, the sample size is small but still, we were able to draw some significant inferences that will strengthen the existing literature on ovarian masses in children. Second, this is a retrospective study with its disadvantages and biases and is Level 3 evidence. However, this effect was minimized using the uniform process for data collection and excellent inpatient and follow-up records available at our institute. Finally, although all the patients were from a single center, they were operated on in 2 units headed by two different surgeons with different experience and expertise which may have affected some intraoperative decisions. However, this effect was minimized by the use of a similar COG protocol for the management of ovarian masses followed in both units. CONCLUSIONS Pediatric ovarian masses often pose a diagnostic dilemma, and the real challenge is in differentiating the small percentage of malignant/borderline malignant lesions from the larger number of nonneoplastic/benign ones. Imaging and tumor markers are the most important preoperative parameters to make this differentiation of benign from malignant ovarian masses. Management of these masses must be individualized based on histopathology, staging, and patient factors. Declaration of patient consent The authors certify that they have obtained all appropriate patient consent forms. In the form, the patients) have given their consent for their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published, and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed. Ethical approval All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Ethical approval was waived in view of the retrospective nature of the study, and the patient identity and details were not revealed in any part of the manuscript or figures. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.